ARTICLE | Clinical News
Angiozyme: Began Phase II study
February 12, 2001 8:00 AM UTC
Ribozyme Pharmaceuticals Inc. (RZYM), Boulder, Colo. Product: Angiozyme Business: Cancer Therapeutic category: Angiogenesis Target: VEGFr Description: Synthetic ribozyme inhibitor of vascular endothe...